A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: A Southwest Oncology Group Study

R. P. Whitehead, T. Fleming, J. S. Macdonald, P. J. Goodman, J. Neefe, T. J. Braun, L. J. Swinnen, Evan M Hersh

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Tumor necrosis factor (TNF) induces hemorrhagic necrosis in the Meth A mouse tumor model and has shown cytostatic and cytotoxic antitumor effects against a wide range of human tumors both in vitro and as human tumor xenografts in nude mice. Because of in vitro activity against colorectal tumors and antitumor responses in colon cancer patients in phase I trials, this phase II study was undertaken. Patients were treated with TNF administered daily for 5 days/week every other week at a dose of 150 μg/m2/day as a 30-min i.v. infusion. One cycle consisted of 4 weeks of treatment over an 8-week period. Twenty-five patients have been entered into this study with three patients ineligible. The 22 eligible patients ranged in age from 38-73 years and had initial performance status of 0 in 10 patients, 1 in 10 patients, and 2 in 2 patients. No complete or partial responses were seen. Two patients had stable disease (no response) and 18 patients progressed. Two patients had no evaluation and were assumed to have had no response. The response rate is therefore 0%, with a 95% exact confidence interval of 0% to 15%. There was one grade 4 toxicity consisting of nausea and vomiting. Most common grade 3 toxicities were chills and fever in four patients, nausea and vomiting in three patients, and anemia and elevated liver enzymes in two patients. Headache, myalgia/arthralgia, and elevated serum triglycerides were frequently seen. Mildly elevated levels of fibrin split products were seen after TNF treatment in 5/13 evaluable patients and one ineligible patient. One thrombotic episode occurring in a subclavian vein and possibly related to central line placement or TNF treatment occurred. In this dose and schedule, TNF is ineffective for the treatment of metastatic colorectal adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)588-591
Number of pages4
JournalJournal of Biological Response Modifiers
Volume9
Issue number6
StatePublished - 1990

Fingerprint

Adenocarcinoma
Tumor Necrosis Factor-alpha
Nausea
Vomiting
Subclavian Vein
Neoplasms
Chills
Myalgia
Arthralgia
Cytostatic Agents
Therapeutics
Fibrin
Heterografts
Nude Mice
Colonic Neoplasms
Headache
Anemia
Colorectal Neoplasms
Appointments and Schedules
Triglycerides

Keywords

  • Colorectal adenocarcinoma
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma : A Southwest Oncology Group Study. / Whitehead, R. P.; Fleming, T.; Macdonald, J. S.; Goodman, P. J.; Neefe, J.; Braun, T. J.; Swinnen, L. J.; Hersh, Evan M.

In: Journal of Biological Response Modifiers, Vol. 9, No. 6, 1990, p. 588-591.

Research output: Contribution to journalArticle

Whitehead, R. P. ; Fleming, T. ; Macdonald, J. S. ; Goodman, P. J. ; Neefe, J. ; Braun, T. J. ; Swinnen, L. J. ; Hersh, Evan M. / A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma : A Southwest Oncology Group Study. In: Journal of Biological Response Modifiers. 1990 ; Vol. 9, No. 6. pp. 588-591.
@article{961d72a82d094b20852413b200c338b4,
title = "A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: A Southwest Oncology Group Study",
abstract = "Tumor necrosis factor (TNF) induces hemorrhagic necrosis in the Meth A mouse tumor model and has shown cytostatic and cytotoxic antitumor effects against a wide range of human tumors both in vitro and as human tumor xenografts in nude mice. Because of in vitro activity against colorectal tumors and antitumor responses in colon cancer patients in phase I trials, this phase II study was undertaken. Patients were treated with TNF administered daily for 5 days/week every other week at a dose of 150 μg/m2/day as a 30-min i.v. infusion. One cycle consisted of 4 weeks of treatment over an 8-week period. Twenty-five patients have been entered into this study with three patients ineligible. The 22 eligible patients ranged in age from 38-73 years and had initial performance status of 0 in 10 patients, 1 in 10 patients, and 2 in 2 patients. No complete or partial responses were seen. Two patients had stable disease (no response) and 18 patients progressed. Two patients had no evaluation and were assumed to have had no response. The response rate is therefore 0{\%}, with a 95{\%} exact confidence interval of 0{\%} to 15{\%}. There was one grade 4 toxicity consisting of nausea and vomiting. Most common grade 3 toxicities were chills and fever in four patients, nausea and vomiting in three patients, and anemia and elevated liver enzymes in two patients. Headache, myalgia/arthralgia, and elevated serum triglycerides were frequently seen. Mildly elevated levels of fibrin split products were seen after TNF treatment in 5/13 evaluable patients and one ineligible patient. One thrombotic episode occurring in a subclavian vein and possibly related to central line placement or TNF treatment occurred. In this dose and schedule, TNF is ineffective for the treatment of metastatic colorectal adenocarcinoma.",
keywords = "Colorectal adenocarcinoma, Tumor necrosis factor",
author = "Whitehead, {R. P.} and T. Fleming and Macdonald, {J. S.} and Goodman, {P. J.} and J. Neefe and Braun, {T. J.} and Swinnen, {L. J.} and Hersh, {Evan M}",
year = "1990",
language = "English (US)",
volume = "9",
pages = "588--591",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma

T2 - A Southwest Oncology Group Study

AU - Whitehead, R. P.

AU - Fleming, T.

AU - Macdonald, J. S.

AU - Goodman, P. J.

AU - Neefe, J.

AU - Braun, T. J.

AU - Swinnen, L. J.

AU - Hersh, Evan M

PY - 1990

Y1 - 1990

N2 - Tumor necrosis factor (TNF) induces hemorrhagic necrosis in the Meth A mouse tumor model and has shown cytostatic and cytotoxic antitumor effects against a wide range of human tumors both in vitro and as human tumor xenografts in nude mice. Because of in vitro activity against colorectal tumors and antitumor responses in colon cancer patients in phase I trials, this phase II study was undertaken. Patients were treated with TNF administered daily for 5 days/week every other week at a dose of 150 μg/m2/day as a 30-min i.v. infusion. One cycle consisted of 4 weeks of treatment over an 8-week period. Twenty-five patients have been entered into this study with three patients ineligible. The 22 eligible patients ranged in age from 38-73 years and had initial performance status of 0 in 10 patients, 1 in 10 patients, and 2 in 2 patients. No complete or partial responses were seen. Two patients had stable disease (no response) and 18 patients progressed. Two patients had no evaluation and were assumed to have had no response. The response rate is therefore 0%, with a 95% exact confidence interval of 0% to 15%. There was one grade 4 toxicity consisting of nausea and vomiting. Most common grade 3 toxicities were chills and fever in four patients, nausea and vomiting in three patients, and anemia and elevated liver enzymes in two patients. Headache, myalgia/arthralgia, and elevated serum triglycerides were frequently seen. Mildly elevated levels of fibrin split products were seen after TNF treatment in 5/13 evaluable patients and one ineligible patient. One thrombotic episode occurring in a subclavian vein and possibly related to central line placement or TNF treatment occurred. In this dose and schedule, TNF is ineffective for the treatment of metastatic colorectal adenocarcinoma.

AB - Tumor necrosis factor (TNF) induces hemorrhagic necrosis in the Meth A mouse tumor model and has shown cytostatic and cytotoxic antitumor effects against a wide range of human tumors both in vitro and as human tumor xenografts in nude mice. Because of in vitro activity against colorectal tumors and antitumor responses in colon cancer patients in phase I trials, this phase II study was undertaken. Patients were treated with TNF administered daily for 5 days/week every other week at a dose of 150 μg/m2/day as a 30-min i.v. infusion. One cycle consisted of 4 weeks of treatment over an 8-week period. Twenty-five patients have been entered into this study with three patients ineligible. The 22 eligible patients ranged in age from 38-73 years and had initial performance status of 0 in 10 patients, 1 in 10 patients, and 2 in 2 patients. No complete or partial responses were seen. Two patients had stable disease (no response) and 18 patients progressed. Two patients had no evaluation and were assumed to have had no response. The response rate is therefore 0%, with a 95% exact confidence interval of 0% to 15%. There was one grade 4 toxicity consisting of nausea and vomiting. Most common grade 3 toxicities were chills and fever in four patients, nausea and vomiting in three patients, and anemia and elevated liver enzymes in two patients. Headache, myalgia/arthralgia, and elevated serum triglycerides were frequently seen. Mildly elevated levels of fibrin split products were seen after TNF treatment in 5/13 evaluable patients and one ineligible patient. One thrombotic episode occurring in a subclavian vein and possibly related to central line placement or TNF treatment occurred. In this dose and schedule, TNF is ineffective for the treatment of metastatic colorectal adenocarcinoma.

KW - Colorectal adenocarcinoma

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=0025662031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025662031&partnerID=8YFLogxK

M3 - Article

C2 - 2074444

AN - SCOPUS:0025662031

VL - 9

SP - 588

EP - 591

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 6

ER -